在长期COVID综合征中SGLT2抑制剂:有潜在的作用吗?
Paul Zimmermann1,2,3, Harald Sourij4, Felix Aberer4
1Division of Exercise Physiology and Metabolism, BaySpo-Bayreuth Center of Sport Science, University of Bayreuth, 95440 Bayreuth, Germany.
-葡萄糖共运输体2 (SGLT2) 抑制剂正在被探索作为长期COVID综合征 (LCS) 的潜在治疗方法. 本综述检查了它们对持续的COVID-19症状的抗炎和全身益处.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 传染性疾病 传染性疾病
背景情况:
- 由于COVID-19的流行,导致了全球健康危机.
- 长期COVID综合征 (LCS) 涉及持续的炎症和多器官影响,包括呼吸障碍和疲劳.
- 心脏生理学和代谢障碍与严重的COVID-19和LCS有关.
研究的目的:
- 在管理LCS时检查-葡萄糖共运输体2 (SGLT2) 抑制剂的合理性.
- 探索SGLT2抑制剂超出其已知的心脏-脏-代谢作用的潜在抗炎和全身益处.
- 讨论SGLT2抑制剂对COVID-19结果的潜在优缺点.
主要方法:
- 现有文献的叙述性审查.
- 讨论SGLT2抑制剂的作用机制.
- 在LCS中分析潜在的治疗应用.
主要成果:
- 由于潜在的抗炎和全身效应,SGLT2抑制剂在治疗LCS方面表现有前途.
- 已确定的心脏-脏-代谢益处可能会扩展到LCS管理.
- 需要进一步的研究来证实有效性和安全性.
结论:
- SGLT2 抑制剂代表了长期COVID综合征的潜在治疗途径.
- 它们的抗炎性质需要进行调查,以缓解持续的COVID-19症状.
- 正在进行的研究将澄清SGLT2抑制剂在COVID-19和LCS结果中的作用.
更多相关视频
06:46A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
相关概念视频
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Glucose Absorption Into the Small Intestine
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
